Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
7(100.0%)
7Total
Phase 2(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07542158Phase 2Enrolling By Invitation

Ultralow Dose PET Imaging of 18F-FDOPA

Role: lead

NCT07284576Phase 2Enrolling By Invitation

Ultralow Dose PET Imaging of 18F-flurpiridaz

Role: lead

NCT07012993Phase 2Recruiting

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Role: lead

NCT07284589Phase 2Recruiting

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Role: lead

NCT07284563Phase 2Recruiting

Ultralow Dose PET Imaging for 18F-NaF Uptake

Role: lead

NCT06904313Phase 2Recruiting

Ultralow Dose PET Imaging for PSMA Expression

Role: lead

NCT06956391Phase 2Recruiting

Ultralow Dose PET Imaging of 18F-FDG Uptake

Role: lead

All 7 trials loaded